Hematologic Malignancies

John M. Burke MD Elias Jabbour MD Rami S. Komrokji MD and Shaji Kumar MD review data from key hematologic malignancies presentations at the 2016 American Society of Clinical Oncology Annual Meeting.

Share

Program Content

Activities

  • Heme Malignancies Chicago 2016
    Expert Perspective on the Top Hematologic Malignancy Studies From the 2016 Clinical Oncology Meeting
    Clinical Thought
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 31, 2016

    Expires: May 30, 2017

  • Meta-analysis of Len Maintenance in MM
    Lenalidomide Maintenance after ASCT Improved OS in Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2016

    Expires: June 05, 2017

  • 19-28z CAR T Cells in R/R B-Cell ALL
    19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2016

    Expires: June 05, 2017

  • VEN+LDAC in Untreated AML
    Venetoclax + Low-Dose Cytarabine in Elderly Patients With Untreated AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2016

    Expires: June 05, 2017

  • CTL019 Dosing in R/R ALL
    Fractionated Dosing Optimizes CAR T-Cell Therapy in Adult Relapsed/Refractory ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2016

    Expires: June 05, 2017

  • KPd in R/R MM
    Carfilzomib, Pomalidomide, Dexamethasone Feasible in Patients With Relapsed/Refractory MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2016

    Expires: June 05, 2017

  • Venetoclax in CLL
    Venetoclax Active in Relapsed/Refractory CLL After Treatment With Ibrutinib or Idelalisib
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2016

    Expires: June 05, 2017

  • ASCT Prolongs PFS in NDMM
    Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2016

    Expires: June 06, 2017

  • Ruxolitinib in MF
    COMFORT-1: Final 5-Yr Analysis of Ruxolitinib in Int- or High-Risk Myelofibrosis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2016

    Expires: June 06, 2017

  • Mogamulizumab in R/R ATL
    0761-009: Mogamulizumab in R/R Adult T-Cell Leukemia-Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2016

    Expires: June 06, 2017

  • CPX-351 in High-Risk AML
    First-line CPX-351 Superior to 7 + 3 Induction in Older Patients With High-Risk AML
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2016

    Expires: June 07, 2017

  • Acalabrutinib in CLL
    Phase II Study of Acalabrutinib Monotherapy Demonstrates Activity, Safety in Previously Untreated CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2016

    Expires: June 07, 2017

  • Pembrolizumab in R/R MM
    KEYNOTE-023: Pembrolizumab + Lenalidomide + Dexamethasone Shows Promising Activity and Safety in R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2016

    Expires: June 07, 2017

  • CASTOR: DVd vs Vd in MM
    CASTOR: Daratumumab Added to Bortezomib/Dexamethasone Improves PFS, Response in RR Myeloma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2016

    Expires: June 07, 2017

  • Venetoclax + Vd in R/R MM
    Phase Ib Venetoclax With Bortezomib and Dexamethasone Safe, Active in R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2016

    Expires: June 08, 2017

  • Carfilzomib in R/R MM
    Economic Evaluation: Addition of Carfilzomib to Lenalidomide/Dexamethasone Cost Effective for R/R MM
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 10, 2016

    Expires: June 09, 2017

  • TKI Comparison in Ph+ ALL
    First-line HCVAD + Ponatinib Appears Superior to HCVAD + Dasatinib in Ph+ ALL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 13, 2016

    Expires: June 12, 2017

  • KRD in Early Relapsed MM
    Carfilzomib/Lenalidomide/Low-Dose Dexamethasone in MM With Early Progression: ASPIRE Subgroup Analysis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2016

    Expires: June 13, 2017

  • LEN in CNS Lymphoma
    Lenalidomide Shows Promising Activity in Recurrent CNS Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2016

    Expires: June 13, 2017

  • Downloadable Slideset
    Hematologic Malignancies: A Review of Key Clinical Studies
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 30, 2016

    Expires: August 29, 2017

Faculty

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

ProCE Banner

Supporters

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals